[Osteogenesis imperfecta: a new, early therapeutic approach with biphosphonates. A case report].

Abstract

UNLABELLED:

Management of type III osteogenesis imperfecta (O.I.) (brittle bone disease) is primarily supportive; early introduction of cyclic intravenous pamidronate administration in children younger than 2 years of age is an innovative and promising therapeutic approach.

CASE REPORT:

We present the case of a 6-month-old infant, whose preliminary data have already been partly published, with severe type III O.I. referred because of aching and crumbling from multiple fractures. Cyclic intravenous disodic pamidronate administration improved the clinical status (fracture incidence, pain, growth curve) and biological status (bone density, osseous alkaline phosphatases, urinary desoxypiridoline excretion), allowing a remarkable recovery.

CONCLUSION:

Biphosphonates are a new and innovative therapeutic agent in O.I. Clinical safety, easy administration, and overall efficacy are likely to extend their use in severe type III O.I. from the very first months of life, the time of best efficacy.

• Authors: M Guillot, P Eckart, H Desrosieres, M Amiour, Z al-Jazayri
• Journal: Archives de pediatrie : organe officiel de la Societe francaise de pediatrie (Arch Pediatr) Vol. 8 Issue 2 Pg. 172-5 (Feb 2001) ISSN: 0929-693X [Print] France
• Vernacular Title: Ostéogenèse imparfaite: une nouvelle approche thérapeutique précoce par les biphosphonates. A propos d'une observation.
• PMID: 11232458 (Publication Type: Case Reports, Journal Article)

Chemical References

• Diphosphonates
• Alkaline Phosphatase
• Pamidronate

Topics

• Age Factors
• Alkaline Phosphatase (blood)
• Bone Density
• Diphosphonates (therapeutic use)
• Drug Administration Schedule
• Growth Disorders (etiology)
• Humans
• Infant
• Infusions, Intravenous
• Male
• Osteogenesis Imperfecta (classification, complications, diagnostic imaging, drug therapy, metabolism)
• Pain (etiology)
• Pamidronate
• Radiography
• Treatment Outcome